Director CMC Quality
BrainChild Bio
Director CMC Quality
BrainChild Bio
CAR T therapies targeting CNS tumors
Salary Range: 190000 to 210000 (Currency: USD) (Pay period: per-year-salary)
Director, CMC Quality
Position Summary
BrainChild Bio is seeking an experienced Director, CMC Quality to provide strategic quality leadership across the development and lifecycle management of its cell therapy programs. This role serves as the CMC Quality lead, ensuring phase-appropriate quality oversight, robust control strategies, QC Operations and compliance with regulatory requirements throughout the product lifecycle.
BrainChild Bio is a clinical-stage biotechnology company leading the field in the development of CAR T cell therapies for tumors in the central nervous system (CNS). We are kids-first, prioritizing devastating pediatric brain tumors, with a pipeline that extends our technology platform to adult indications, including glioblastoma and brain metastases. Every member of our team plays a direct role in bringing innovative therapies to patients and familiars with urgent unmet medical needs.
Responsibilities
CMC Quality Leadership
Product Quality Strategy
QC Operations Oversight
External Partner Quality Oversight
Required Qualifications
Preferred Qualifications
Travel
CAR T therapies targeting CNS tumors
What BrainChild Bio does: It develops CAR T cell therapies to treat tumors in the central nervous system, focusing on children first and then expanding to adults with glioblastoma. How its product works: The lead therapy, BCB-276, uses a patient’s own T cells engineered to target B7-H3, and is given directly into the cerebrospinal fluid to reach brain and spine tumors. The company is also advancing a triple-targeting candidate, BCB-214, toward initial glioblastoma testing. How it differs from competitors: BrainChild Bio relies on autologous CAR T cells delivered locoregionally into CSF, with technology licensed from Seattle Children’s and strong ties to that institution, aiming at pediatric DIPG and other CNS cancers. What its goal is: To complete the Phase 2 ILLUMINATE trial to support a future regulatory filing for BCB-276 and to broaden its pipeline for CNS tumors, including early work on glioblastoma, supported by a recent $116 million Series A.
Explore more opportunities at BrainChild Bio